Prelude Therapeutics Inc (PRLD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $275.32M
Last updated: Nov 17, 2026 at 11:05 AM ET
Prelude Therapeutics Inc (PRLD) Earnings: Report Dates and Results
Prelude Therapeutics (PRLD) is expected to report earnings on Mar 8, 2027. In the quarter ended Jun 30, 2026, Prelude Therapeutics reported EPS of -$0.14, above the -$0.17 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PRLD has an expected report date of Mar 8, 2027.
PRLD Earnings Call
The latest PRLD earnings call transcript on file is labeled 2025Q3.
Read the 2025Q3 transcriptEarnings History
Of the 24 quarters below that had an estimate, PRLD beat 17 and missed 7. The widest gap in the table came in the quarter ended Dec 31, 2025, when EPS landed 53.85% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.14 | -$0.17 | -$0.20 - -$0.17 | +17.65% | Beat | N/A | 2 | 1 up, 0 down | Aug 11, 2026 | $5.70M |
| Mar 31, 2026 | -$0.13 | -$0.27 | -$0.27 - -$0.26 | +51.85% | Beat | N/A | 3 | 0 up, 0 down | May 12, 2026 | $4.58M |
| Dec 31, 2025 | -$0.20 | -$0.13 | N/A | -53.85% | Miss | N/A | 1 | 1 up, 0 down | Mar 10, 2026 | $5.64M |
| Sep 30, 2025 | -$0.26 | -$0.35 | -$0.36 - -$0.35 | +25.71% | Beat | N/A | 2 | 0 up, 0 down | Nov 12, 2025 | $6.50M |
| Jun 30, 2025 | -$0.41 | -$0.43 | -$0.43 - -$0.43 | +4.65% | Beat | N/A | 3 | N/A | Aug 14, 2025 | N/A |
| Mar 31, 2025 | -$0.42 | -$0.46 | -$0.47 - -$0.46 | +8.70% | Beat | N/A | 2 | 1 up, 1 down | May 6, 2025 | N/A |
| Dec 31, 2024 | -$0.37 | -$0.47 | -$0.48 - -$0.44 | +20.82% | Beat | N/A | 4 | 4 up, 0 down | Mar 10, 2025 | $4.00M |
| Sep 30, 2024 | -$0.43 | -$0.46 | -$0.50 - -$0.45 | +6.52% | Beat | N/A | 5 | 0 up, 0 down | Nov 6, 2024 | $3.00M |
| Jun 30, 2024 | -$0.46 | -$0.43 | -$0.46 - -$0.39 | -6.98% | Miss | N/A | 4 | 0 up, 0 down | Aug 12, 2024 | N/A |
| Mar 31, 2024 | -$0.42 | -$0.48 | -$0.55 - -$0.44 | +12.50% | Beat | N/A | 4 | 0 up, 0 down | May 7, 2024 | N/A |
| Dec 31, 2023 | -$0.45 | -$0.49 | -$0.52 - -$0.47 | +8.16% | Beat | N/A | 3 | 0 up, 0 down | Feb 15, 2024 | $3.42M |
| Sep 30, 2023 | -$0.45 | -$0.58 | -$0.60 - -$0.56 | +22.41% | Beat | N/A | 3 | 0 up, 0 down | Nov 1, 2023 | N/A |
| Jun 30, 2023 | -$0.54 | -$0.63 | -$0.66 - -$0.61 | +14.29% | Beat | N/A | 3 | 0 up, 0 down | Aug 3, 2023 | N/A |
| Mar 31, 2023 | -$0.58 | -$0.70 | -$0.72 - -$0.63 | +17.14% | Beat | N/A | 4 | 0 up, 0 down | May 8, 2023 | N/A |
| Dec 31, 2022 | -$0.60 | -$0.63 | -$0.65 - -$0.59 | +4.76% | Beat | N/A | 5 | 0 up, 0 down | Mar 15, 2023 | N/A |
| Sep 30, 2022 | -$0.63 | -$0.64 | -$0.65 - -$0.63 | +1.56% | Beat | N/A | 5 | 0 up, 0 down | Nov 14, 2022 | N/A |
| Jun 30, 2022 | -$0.58 | -$0.63 | N/A | +7.94% | Beat | N/A | N/A | 0 up, 0 down | Aug 9, 2022 | N/A |
| Mar 31, 2022 | -$0.63 | -$0.65 | -$0.66 - -$0.64 | +3.08% | Beat | N/A | 3 | 0 up, 0 down | May 10, 2022 | N/A |
| Dec 31, 2021 | -$0.71 | -$0.68 | -$0.70 - -$0.67 | -4.41% | Miss | N/A | 4 | N/A | Mar 16, 2022 | N/A |
| Sep 30, 2021 | -$0.66 | -$0.62 | -$0.65 - -$0.59 | -6.45% | Miss | N/A | 5 | 0 up, 0 down | Nov 12, 2021 | N/A |
| Jun 30, 2021 | -$0.58 | -$0.49 | -$0.53 - -$0.46 | -18.37% | Miss | N/A | 5 | N/A | Aug 12, 2021 | N/A |
| Mar 31, 2021 | -$0.47 | -$0.42 | -$0.46 - -$0.38 | -11.90% | Miss | N/A | 5 | N/A | May 11, 2021 | N/A |
| Dec 31, 2020 | -$0.45 | -$0.47 | -$0.58 - -$0.39 | +4.26% | Beat | N/A | 4 | N/A | Mar 16, 2021 | N/A |
| Sep 30, 2020 | -$0.38 | -$0.34 | -$0.60 - -$0.25 | -11.76% | Miss | N/A | 3 | N/A | Nov 10, 2020 | N/A |
| Jun 30, 2020 | -$5.50 | -$0.39 | N/A | N/A | N/A | N/A | N/A | N/A | Sep 25, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.29, after -$1.68 the year before. It was -$6.33 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.29 | N/A |
| Dec 31, 2024 | -$1.68 | N/A |
| Dec 31, 2023 | -$2.02 | N/A |
| Dec 31, 2022 | -$2.44 | N/A |
| Dec 31, 2021 | -$2.42 | N/A |
| Dec 31, 2020 | -$6.33 | N/A |
Earnings Calls
The only earnings call listed below, 2025Q3 for the period ended Sep 30, 2025, runs about 4,800 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q3 | Sep 30, 2025 | 4,800 | 8 |
2025Q3 Earnings Call
Opening remarks
Bryant Lim CFO and Chief Legal Officer Thank you, operator. During today's call, we will make forward-looking statements based on current expectations, including statements concerning anticipated discovery, preclinical and future clinical development activities for our product candidates; the potential safety, efficacy, benefits and addressable market for our product candidates and clinical trial results for our product candidates; together with other statements regarding our plans, prospects and expectations. Such statements represent our judgments as of today, are not promises or guarantees, and as you know, may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Please refer to our filings with the SEC, which are available through the Investor Relations section of our website for information concerning risk factors that may affect the company. We undertake no obligation to update forward-looking statements, except as required by law. During this call, we will also be referring to certain slides from our corporate presentation that are available on the Investors section of our corporate website under Presentations and Events. Also on this call are Kris Vaddi, Prelude's Founder and Chief Executive Officer; as well as Peggy Scherle, our Chief Scientific Officer; and Sean Brusky, our Chief Business Officer. I will now turn the call over to Kris to kick things off.
Kris Vaddi CEO Thank you, Bryant, and good morning to everyone joining us today. Over the past quarter, we've made several strategic decisions to sharpen our research and development focus, optimize capital allocation, and align our business strategy with programs that offer the highest likelihood of success. These steps strengthen our ability to fulfill our mission of discovering and developing transformative medicines that can significantly enhance patient outcomes in cancer. Importantly, as part of these efforts, we've also improved our financial position, giving us additional cash runway to move our lead programs into clinical development. Looking ahead, our main focus will be on quickly advancing two development candidates that we believe present compelling opportunities for our investors, both expected to enter clinical trials in 2026. The first is a selective inhibitor for JAK2V617F aimed at treating myeloproliferative neoplasms (MPN). The second is a selective degrader targeting KAT6A for ER-positive breast cancer. Both programs address clinically validated pathways with the potential for efficacy and safety differentiation in early clinical development. Furthermore, we believe these molecules will significantly broaden clinical options compared to existing treatments for the cancers we're targeting. Meanwhile, our discovery team has made considerable progress in developing next-generation antibody-drug conjugates, known as degrader antibody conjugates or DACs. Our early-stage DAC program, which targets mutant calreticulin (mCALR) - a very promising target in MPN - shows potential to achieve greater clinical and molecular responses based on our preclinical studies.
Frequently Asked Questions About PRLD
When is Prelude Therapeutics's next earnings date?
Prelude Therapeutics's next earnings report is expected for Mar 8, 2027.
Did PRLD beat earnings estimates last quarter?
Yes. Prelude Therapeutics reported EPS of -$0.14 for the quarter ended Jun 30, 2026, above the -$0.17 estimate, a 17.65% surprise.
What EPS do analysts expect from PRLD next quarter?
The consensus EPS estimate for Prelude Therapeutics for the quarter ending Dec 31, 2026 is -$0.17 from 6 analysts, with estimates from -$0.22 to -$0.15.
How often does PRLD beat earnings estimates?
Prelude Therapeutics beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +10.26%.
PRLD pages: Overview, Earnings, Forecast, Financials, Competitors